RNF32 Inhibitors
RNF32 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of RNF32, a member of the RING finger protein family, which plays a role in the ubiquitin-proteasome system (UPS). RNF32 contains a RING domain, a structural motif that facilitates the attachment of ubiquitin molecules to substrate proteins, marking them for degradation via the proteasome. Ubiquitination is a critical cellular process involved in maintaining protein homeostasis, regulating signal transduction, and controlling the degradation of misfolded or damaged proteins. By inhibiting RNF32, these compounds block its E3 ubiquitin ligase activity, preventing the tagging of target proteins with ubiquitin, which can disrupt normal protein turnover and affect cellular pathways dependent on regulated protein degradation.
The design of RNF32 inhibitors requires a thorough understanding of the protein's structural features, particularly its RING domain, which is responsible for its enzymatic activity. Inhibitors typically target the RING domain or its interaction sites with E2 ubiquitin-conjugating enzymes, effectively blocking the transfer of ubiquitin to substrate proteins. This inhibition disrupts the protein degradation pathways in which RNF32 plays a role, providing a means to study the specific cellular processes controlled by this ubiquitin ligase. Researchers often employ techniques such as X-ray crystallography and molecular modeling to identify critical binding pockets and design inhibitors with high specificity for RNF32. Achieving specificity is crucial, as many proteins in the ubiquitin-proteasome system share similar structural motifs. RNF32 inhibitors serve as important tools for dissecting the molecular mechanisms of ubiquitination and for exploring the regulatory roles of RNF32 in protein degradation, signaling pathways, and cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 is an inhibitor of the NEDD8-activating enzyme (NAE), which is essential for the neddylation process. Since neddylation can modify the activity of RNF32 by altering its ability to ubiquitinate substrates, inhibition of this upstream process by MLN4924 leads to a reduction in the functional ubiquitin ligase activity of RNF32. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. By doing so, it leads to an accumulation of ubiquitinated proteins, which can saturate the ubiquitin-proteasome system and indirectly inhibit the activity of ubiquitin ligases like RNF32 by reducing the availability of free ubiquitin molecules. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that works similarly to MG132. It specifically inhibits the 20S proteasome, leading to reduced degradation of ubiquitinated proteins and thereby indirectly inhibiting RNF32 by depleting the pool of free ubiquitin and ubiquitin-conjugating enzymes necessary for its ligase activity. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
PYR-41 is a ubiquitin-activating enzyme E1 inhibitor. By inhibiting E1, PYR-41 prevents the initial step of ubiquitin transfer, which is vital for subsequent transfer to ubiquitin-conjugating enzymes (E2) and ubiquitin ligase enzymes (E3) like RNF32, thus inhibiting its function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a dipeptidyl boronic acid that also functions as a proteasome inhibitor. By blocking the proteolytic function of the 26S proteasome, it indirectly inhibits RNF32 activity by causing a backlog of ubiquitinated proteins that could sequester ubiquitin ligase components. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor, which binds irreversibly to the proteasome, leading to the build-up of ubiquitinated proteins. This impedes the ubiquitin-proteasome system, potentially saturating the ubiquitination machinery and indirectly inhibiting the ubiquitin ligase activity of RNF32. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
IU1 specifically inhibits the deubiquitinating enzyme USP14, which can remove ubiquitin from substrates before their degradation by the proteasome. By blocking USP14, IU1 indirectly enhances the degradation of proteins, which can lead to a decrease in free ubiquitin, indirectly inhibiting the ubiquitin ligase function of RNF32. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a tetrapeptide epoxyketone and a proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, leading to the accumulation of ubiquitinated proteins and indirectly inhibiting the ubiquitin ligase activity of RNF32. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an orally bioavailable proteasome inhibitor that, similar to Carfilzomib, targets and inhibits the activity of the proteasome, resulting in the accumulation of ubiquitinated proteins and indirectly inhibiting RNF32 by reducing the efficiency of the ubiquitin ligase pathway. | ||||||